Cytokinetics Inc. (CYTK)
Cytokinetics Inc. (CYTK) is a biopharmaceutical company focused on developing muscle biology-based therapies for debilitating diseases. The company's key areas of interest include treatments for conditions such as amyotrophic lateral sclerosis (ALS), heart failure, and other muscle-related disorders. Cytokinetics leverages its expertise in muscle contractility and cytoskeletal proteins to discover, develop, and commercialize innovative therapeutic agents.
Company News
A class action lawsuit has been filed against Cytokinetics alleging securities fraud related to misleading statements about the New Drug Application submission and approval process for aficamten, potentially causing investor losses.
The FDA has extended the PDUFA action date for Cytokinetics' new drug application for aficamten, an experimental heart drug, by three months to allow for a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS).
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
These two biotech stocks could be big winners in the years ahead.